Microbiome therapies: a maturing movement europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
Regulatory News: As of December 31, 2022, cash and cash equivalents were €35.2 million (prior to the capital raise in February 2023) and turnover was €1.4 million Significant milestones
Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma
News provided by
Share this article
STOCKHOLM, March 8, 2021 /PRNewswire/ Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO
), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announced that it strengthens the leadership of the European operations by appointing Andrea Passalacqua as General Manager in Europe, and Pamela Bacon as Head of Medical Affairs Europe. The Company also announced that it opens an Early Access Program across Europe to address the significant need of new treatment alternatives in multiple myeloma. As previously announced, Oncopeptides will also seek a Conditional Marketing Authorization of melphalan flufenamide in triple class refractory multiple myeloma, during second quarter of 2021.
Oncopeptides strengthens leadership in Europe and opens an Early Access Program in multiple myeloma prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.